Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Results of a Randomised Phase III Trial (METEOR)
The METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma (RCC) was reported by Prof Choueiri at the European Cancer Congress 2015. This presentation follows the publication in the New England Journal of Medicine of the METEOR trial back-to-back with the CheckMate 025 trial...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2015-11-01
|
| Series: | European Medical Journal Oncology |
| Subjects: | |
| Online Access: | http://emjreviews.com/wp-content/uploads/Cabozantinib-Versus-Everolimus-in-Patients-with-Advanced-Renal-Cell-Carcinoma-Results-of-a-Randomised-Phase-III-Trial.pdf |